Novo Nordisk (NYSE:NVO) continues to face supply shortages for its Wegovy (semaglutide) pens, which are FDA approved for weight management. Against that backdrop, a growing number of companies have begun selling compounded versions of the drug. Drug compounding involves “combining, mixing, or altering ingredients to create a medication tailored to the needs of an individual patient,”…